Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

The global prevalence of non‐alcoholic fatty liver disease (NAFLD) is rising, along with the
epidemic of diabesity. NAFLD is present in> 70% of individuals with type 2 diabetes …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high
risk of liver-related and all-cause morbidity and mortality. We investigated the efficacy and …

PAR2 promotes impaired glucose uptake and insulin resistance... : Hepatology PAR2 promotes
impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference …

Glycemic burden and the risk of adverse hepatic outcomes in... : Hepatology Glycemic burden
and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 …

Background and Aims NASH is a common disease associated with increased rates of
thromboembolism (TE). Although exercise training can lessen thrombotic risk in patients with …

Lanifibranor, a pan-PPAR agonist, improves liver histology in patients with metabolic
dysfunction-associated steatohepatitis (MASH), who have poor cardiometabolic health …

Abstract Background and Aims Insulin resistance and poor glycemic control are key drivers
of the development of NAFLD and have recently been shown to be associated with fibrosis …

Insulin resistance is implicated in both the pathogenesis of nonalcoholic fatty liver disease
(NAFLD) and its progression from steatosis to steatohepatitis, cirrhosis, and even …